An allosteric site in the T-cell receptor Cβ domain plays a critical signalling role

Kannan Natarajan, Andrew C. McShan, Jiansheng Jiang, Vlad K. Kumirov, Rui Wang, Huaying Zhao, Peter Schuck, Mulualem E. Tilahun, Lisa F. Boyd, Jinfu Ying, Ad Bax, David H. Margulies, Nikolaos G. Sgourakis

The molecular mechanism through which the interaction of a clonotypic αβ T-cell receptor (TCR) with a peptide-loaded major histocompatibility complex (p/MHC) leads to T-cell activation is not yet fully understood. Here we exploit a high-affinity TCR (B4.2.3) to examine the structural changes that accompany binding to its p/MHC ligand (P18-I10/H2-Dd). In addition to conformational changes in complementarity-determining regions (CDRs) of the TCR seen in comparison of unliganded and bound X-ray structures, NMR characterization of the TCR Cβ-chain dynamics reveals significant chemical shift effects in sites removed from the MHC-binding site. Remodelling of electrostatic interactions near the Cβ H3 helix at the membrane-proximal face of the TCR, a region implicated in interactions with the CD3 co-receptor, suggests a possible role for an allosteric mechanism in TCR signalling. The contribution of these TCR residues to signal transduction is supported by mutagenesis and T-cell functional assays.

DOI: 10.1038/ncomms15260
A key step in T-cell-mediated adaptive immunity is the triggering of cell-surface αβ T-cell receptors (TCR) by peptide-loaded major histocompatibility complex (p/MHC) proteins on target antigen-presenting cells. TCR-α and -β polypeptide chains are encoded by genes assembled by recombinatorial assortment of V- and J- and D-J gene segments, respectively, and non-templated nucleotides added at junctions of rearrangement during T-cell ontogeny in the thymus. Encounter of particular clonally expressed TCR with cognate p/MHC ligand triggers a signalling cascade leading to a variety of cellular programmes including thymic selection, proliferation, cytokine production and differentiation into effector and memory T cells.

Whereas antigen specificity is dictated by the amino-terminal variable (V) domains of the αβ-receptor, signalling function is mediated by the non-covalently associated co-receptor CD3γε, δε and εζ dimers, which bear cytoplasmic immunoreceptor tyrosine-based activation motifs (ITAMs). Ligand binding to the TCR/CD3 complex extracellularly initiates intracellular signalling through Src kinase-mediated phosphorylation of these ITAMs. In addition to their signalling function, CD3 subunits are also required for stable cell-surface expression of the TCR/CD3 complex. Mechanistic details concerning the transmission of signals from the extracellular domains of the TCR to the intracellular ITAMs are incomplete, and are the subject of considerable interest, the importance of which is highlighted by diseases associated with dysfunction of this cellular process, the immunosuppressant role of therapeutic antibodies targeting the TCR/CD3 complex and the potential of synthetic TCRs towards immunotherapeutic applications. Efforts to understand the molecular basis of TCR-mediated signalling have relied largely on biophysical, structural and functional approaches. Binding of p/MHC to the TCR induces structural changes at the cytoplasmic face of the TCR/CD3 complex, as evidenced by the accessibility of a polyproline sequence in the CD3ε cytoplasmic tail, and the repositioning of Tyr residues within the CD3 cytoplasmic ITAMs from a relatively inaccessible membrane-associated form to a cytoplasmically oriented, kinase-accessible conformation. However, the molecular mechanism by which p/MHC binding to the TCR is communicated to the associated CD3 subunits for signalling remains unknown.

To gain further insight into the dynamics of TCR/MHC interactions, we employ complementary biophysical methods to examine the high-affinity B4.2.3 TCR in both the liganded and unliganded states. X-ray structures indicate a large rearrangement of the complementarity-determining region 3 (CDR3) loops upon binding. In addition, chemical shift mapping utilizing complementary backbone amide and side-chain methyl NMR probes reveal several residues in the Cβ domain of the TCR, distant from the ligand-binding interface and close to a putative CD3-binding site, that show significant perturbations upon ligand binding. Finally, mutational and functional analyses suggest a critical role of these allosteric sites in signal transduction. These results indicate a dynamic activation mechanism, where p/MHC recognition by the CDRs triggers conformational remodelling of interactions near the Cβ H3 helix at the membrane-proximal face of the TCR.

**Results**

TCR binds to its pMHC ligand with high affinity. The B4.2.3 T-cell hybridoma, derived from a BALB/c mouse immunized with P18-I10 (RGPGRAFVTI), is sensitive to picomolar concentrations of peptide presented by the MHC-I molecule, H2-Dd (refs 16,17). To probe the affinity of interactions between the TCR and p/MHC, we first employed surface plasmon resonance (SPR) where immobilized P18-I10/H2-Dd was offered graded concentrations of the B4.2.3 TCR. The measured affinity ($K_D$) is ~0.54 µM (Fig. 1a), and no binding of the TCR was detected to H2-Dd displaying the motif peptide (MTF) AGPARAAAL, a negative control (Fig. 1b). As TCR affinities for p/MHC ligands span a wide range of $K_D$ from 0.5 to > 100 µM (ref. 18), this affinity is among the highest reported for a naturally occurring TCR.

To explore the TCR/MHC interaction in a complementary assay, we employed sedimentation velocity analytical ultracentrifugation, which permits assessment of the stoichiometry as well as the affinity of the interaction. The B4.2.3 TCR interacts with P18-I10/H2-Dd strongly over a broad range of concentrations (0.1–20 µM of each component) displaying a characteristic concentration-dependent sedimentation coefficient distribution, indicative of a greater time average of molecules in complex as a function of concentration (Fig. 1c). The limiting sedimentation coefficient of ~5S is consistent with a 1:1 stoichiometry, considering the size and shape of the individual components. The strong interaction of the TCR with the cognate P18-I10/H2-Dd ligand contrasts sharply with mixtures of B4.2.3 TCR and MTF/H2-Dd (Fig. 1d), both of which sediment at a concentration-independent velocity of 3.6S. To determine the binding affinity, we analysed the isothermal signal weighted-average sedimentation coefficient ($s_w$) using the $s_c$ values determined from the $s_c$ distributions. A simple 1:1 association model with affinity ($K_D$) of 0.23 µM fits the data well (95% confidence interval: 0.14–0.40 µM). Thus, the B4.2.3 recombinant TCR interacts with P18-I10/H2-Dd with high affinity, in two distinct biophysical assays, consistent with the high peptide sensitivity of the T-cell hybridoma in functional assays.

TCR uses plasticity in the CDR3 loops to recognize pMHC. To elucidate the details of the ligand/receptor interaction, we determined the crystal structures of both free and p/MHC-bound states of the B4.2.3 TCR. The unliganded TCR crystallized in the P31 space group, with three heterodimers in the asymmetric unit (data collection and refinement statistics are provided in Table 1). The P18-I10/H2-Dd/B4.2.3 complex formed crystals in the C2 space group and diffracted to 2.1 Å, revealing a structure with an overall orientation of the TCR on P18-I10/H2-Dd that conforms to previously elucidated general principles (Fig. 2a). The germline-encoded CDR1 and CDR2 loops of the TCR α-chain are positioned towards the C-terminal half of the H2-Dd α2 helix, resulting in a diagonal orientation mode (Fig. 2b). The resulting crossing angle calculated as described is 30°, within the range observed for the majority of stimulatory TCR/MHC complexes (22°–87°; ref. 22). The shape complementarity index of the interface is 0.71 (1.0 is a perfect match), and is among the highest observed for any TCR/MHC complex.

A summary of the interactions between selected residues of the CDRs with the MHC α1 and α2 helices and peptide is shown in Fig. 2c. While α- and β-subunits contribute almost equally to the 1,771 Å² area of interaction between B4.2.3 and H2-Dd (calculated without peptide), nine of ten hydrogen bonds at the binding interface are provided by the β-chain CDRs. Thus, this pMHC/TCR interface is dominated by Vβ interactions within the broad range observed for many different pMHC/TCR complexes.

Superposition of the α- and β-chains of the liganded B4.2.3 TCR with their unliganded counterparts reveals marked changes in the disposition of the CDR3α and CDR3β loops, with little alteration discernible in CDR1 and CDR2 or in the C domains (Supplementary Fig. 1a–d) as observed in other TCRs. In the structures examined here, CDR3α, spanning Ala95 to Lys102, undergoes a large conformational change upon ligand binding, in particular a 9.1 Å displacement of the Cα atom of Asp99 of the first molecule in the asymmetric unit of the unliganded TCR compared to the same atom in the liganded TCR (Supplementary
Fig. 1b). The movement projects the CDR3α loop into the peptide-binding groove, and allows interactions of the Phe97 side chain with the peptide backbone of Gly2 and Gly4. This is illustrated by a 9.2 Å displacement of the Cα atom of the Phe97 side chain from the free to bound form. CDR3β, from Ser92 to Val99, is displaced inwards on ligand binding by 3.1 Å as measured at the Cα of His96. Thus, the X-ray structures indicate large movements of the CDR3α and β loops upon p/MHC engagement that are critical for achieving a highly complementary interface. The extensive interface and hydrogen-bonding network between the α- and β-CDR domains with the P18-I10 peptide suggests an enthalpic complementary interface. The extensive interface and biochemically.

**Increased dynamics in regions of the TCR β-chain in solution.**
To gain insight into the dynamics of the B4.2.3 TCR in solution, in both its free and P18-I10/H2-Dd-bound states, we prepared TCR samples for NMR labelled at the α-chain alone by in vitro assembly of unlabelled α-chain with triple-labelled (2H,13C,15N) or AILV side-chain methyl-labelled β-chain. The resulting proteins showed well-dispersed spectra, indicating stable, properly conformed monomeric TCR, free of aggregation or degradation (Fig. 3a and Supplementary Fig. 2).

Previous studies have established strategies for obtaining NMR assignments of TCR backbone atoms using TROSY-based methods under extensive perdeuteration of the α and β-chains. Here we employed a multipronged approach for assignment and cross-validation of both backbone amide and side-chain methyl resonances of isotopically labelled β-chain TCR samples (outlined in Supplementary Fig. 2). First, backbone amide chemical shifts in the 2D 1H-15N TROSY-HSQC were assigned sequentially utilizing a combination of three-dimensional (3D) HNCA, 3D HN(CA)CB and 3D HNCO experiments recorded on a triple-labelled sample. Second, Ile 13Cα, Leu 13Cα/13Cβ2, Val 13Cγ1/13Cγ2 chemical shift assignments were obtained from 3D HMQCM[CG]CBCA methyl out-and-back experiments recorded on a selectively methyl-labelled sample (Supplementary Fig. 3). Backbone amide assignments obtained using the J-correlated experiments were validated by acquiring amide-to-amide NOEs in TROSY-based 3D HN-CαHαN nuclear Overhauser enhancement spectroscopy (NOESY) experiments, while side-chain methyl assignments were validated with NOE connectivities obtained from 3D Hα-CαHαM and 3D CαM-CαHαM SOFAST NOESY experiments. Close comparison of the NOE crosspeak intensities to their corresponding distances in the X-ray structure further permitted stereospecific disambiguation of the geminal Leu...
On the basis of the assignments of backbone $^1$H, $^{15}$NH, $^{13}$C the asymmetric unit (Supplementary Fig. 1d). Observed for the same residues among the three TCR molecules in is consistent with the multiple crystallographic conformations due to conformational exchange line-broadening, suggesting the (Supplementary Fig. 6) were absent in the TROSY spectra, likely probes towards mapping dynamics of the TCR backbone assignments we obtained a complementary network of of complete, stereospecific assignments of methyl groups to our presented in Supplementary Figs 4 and 5. Thus, with the addition cross-validation strategy for two selected regions of the TCR. Examples of our sequential assignment and NOESY-based Leu non-Pro residues and side-chain methyl assignment of 100% Ile allowed us to achieve backbone amide assignments for 90% of 3D CM-NHN SOFAST NOESY experiments29. This approach 4

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms15260 | www.nature.com/naturecommunications

$^{13}$C$_b$/1$^{13}$C$_b$ and Val $^{13}$C$_g$/1$^{13}$C$_g$2 resonances. Finally, the combined backbone amide and side-chain methyl assignments were cross-validated using NOEs obtained from 3D HN-CM-HM and 3D CM-NH$_3$ SOFAST NOESY experiments29. This approach allowed us to achieve backbone amide assignments for 90% of non-Pro residues and side-chain methyl assignment of 100% Ile$_{81}$, Leu$_{161}$/82, Val$_{31}$/81 and Ala$\beta$ methyls for $\beta$-chain labelled TCR. Examples of our sequential assignment and NOESY-based cross-validation strategy for two selected regions of the $\beta$-chain are presented in Supplementary Figs 4 and 5. Thus, with the addition of complete, stereospecific assignments of methyl groups to our backbone assignments we obtained a complementary network of probes towards mapping dynamics of the TCR $\beta$-chain in solution.

The backbone assignments and NOE connectivity patterns further confirm the structural features of the TCR $\beta$-chain, including the identification of all conserved Ig domain disulfide bonds in an oxidized form as evidenced by the $^{13}$C$_b$ and $^{13}$C$_g$ chemical shifts of the four Cys residues (22, 90 in V$\beta$ and 141, 202 in C$\beta$), as well as the observation of a single peak for all residues in the vicinity of the disulfides. Resonances from several residues within the $\beta$-chain CDR loops, CC' loop and FG loop (Supplementary Fig. 6) were absent in the TROSY spectra, likely due to conformational exchange line-broadening, suggesting the sampling of alternative environments on a ms–ms timescale. This is consistent with the multiple crystallographic conformations observed for the same residues among the three TCR molecules in the asymmetric unit (Supplementary Fig. 1d).

The NMR backbone chemical shifts are highly sensitive probes of the local environment and secondary structure of the molecule. On the basis of the assignments of backbone $^1$H, $^{15}$N$^H$, $^{13}$C$_a$, $^{13}$C$_b$ and $^{13}$CO atoms, we used TALOS-N$^30$ to calculate the secondary structure index and found these predictions to be in good agreement with the DSSP$^{31}$ annotation of our X-ray structure of the free TCR (Fig. 3c,d). When provided with near-complete assignments, the detail of structural information contained in the chemical shifts analysis is highlighted by the robust prediction of the boundaries for the H3 and H4 $\alpha$-helices in the $\beta$-chain, as well as the $\beta_{50}$ helical segment (residues 113–115) located in the linker between V$\beta$ and C$\beta$ (shown as red bars in Fig. 3c, and coloured red in the diagram of Fig. 3d). The chemical shift-derived order parameter (RCI-S$^2$), expressed in the range 0–1 with 0 indicating a random coil and 1 a fully ordered backbone structure, further reveals regions of increased disorder. As opposed to the more detailed model-free order parameters,$^{32}$ derived from fitting $^{15}$N relaxation rates and $^{15}$N-$^1$H NOE ratios that probe ps–ns timescale motions directly, this analysis is based on a statistical comparison of backbone chemical shifts with database values for random coils using an empirical formula parameterized by comparison to molecular dynamics simulations.$^{33}$ Among regions of the TCR $\beta$-chain (lower plot in Fig. 3c), the $\beta_{2}$–$\beta_{3}$ loop (residues 13–17) and the $\beta_{7}$–$\beta_{8}$ loop (residues 68–72), not directly involved in p/MHC binding, as well as the CDR1 and CDR3 loops in the V$\beta$ domain, all show decreased order parameter values with correspondingly increased crystallographic B-factors. The most unstructured region of the $\beta$-chain of the TCR in solution is the FG loop located in C$\beta$ domain, all show decreased order parameter values with correspondingly increased structural fluctuations.$^{32}$ The $\beta$-chain residues involved in the $\alpha$/$\beta$-interface in solution. To characterize the $\alpha$/$\beta$-interface of the B4.2.3 TCR in solution, we

### Table 1 | Data collection and refinement statistics.

|                  | P18-I10/H2-D$^2$/B4.2.3 | B4.2.3 TCR free |
|------------------|-------------------------|-----------------|
| **Data collection** |                         |                 |
| Space group      | C2                      | P$^3_1$         |
| Cell dimensions  |                         |                 |
| $a$, $b$, $c$ (Å) | 210.11, 51.32, 93.74     | 961.1, 961.1, 167.58 |
| $\alpha$, $\beta$, $\gamma$ (°) | 90.00, 97.14, 90.00 | 90.00, 90.00, 120.00 |
| Resolution (Å)   | 29.8±2.1 (2.2-2.1)*      | 48.1±3.00 (3.1-3.0)* |
| $R_{	ext{work}}$ (%) | 8.2 (33.2)*             | 13.1 (48.2)*     |
| $R_{	ext{free}}$ (%) | 16.3 (2.2)*             | 12.6 (1.8)       |
| Completeness (%)  | 97.8 (80.1)*             | 94.4 (65.3)*     |
| Redundancy        | 6.2 (2.6)*               | 5.4 (3.8)*       |
| Estimated twin fraction/law† | 0.0/none                | 0.458/(h-h-k-l)  |
| **Refinement**    |                         |                 |
| Resolution (Å)   | 29.8±2.1 (2.2-2.1)*      | 48.0±3.0 (3.1-3.0)* |
| No. of reflections (unique) | 57,154                  | 32,680          |
| $R_{	ext{work}}$/R$^\text{free}$ (%) | 18.0 (23.2)/22.0 (30.0)* | 24.0 (39.3)/26.8 (44.1)* |
| No. of atoms      | 7,027                   | 10,062          |
| Wilson B-factor   | 36.3                    | 70.3            |
| Average B-factor  | 52.0                    | 91.3            |
| R.m.s deviations  |                         |                 |
| Bond lengths (Å)  | 0.002                   | 0.002           |
| Bond angles (°)   | 0.66                    | 0.80            |
| Ramachandran favoured/outliers (%) | 96.0/0.8 | 96.0/0.2 |
| PDB code         | 5IVX                    | 5IW1            |

* Asterisked numbers correspond to the last resolution shell.
† A pseudo-merohedral twin fraction was estimated by Xtriage in PHENIX.
‡ Refinement $\beta$-interface in solution.
§ A pseudo-merohedral twin fraction was estimated by Xtriage in PHENIX.

No. of reflections (unique) 57,154 32,680

Redundancy 6.2 (2.6)* 5.4 (3.8)*

Completeness (%) 97.8 (80.1)* 94.4 (65.3)*

Estimated twin fraction/law† 0.0/none 0.458/(h-h-k-l)

**Refinement**

|                  | P18-I10/H2-D$^2$/B4.2.3 | B4.2.3 TCR free |
|------------------|-------------------------|-----------------|
| Resolution (Å)   | 29.8±2.1 (2.2-2.1)*      | 48.0±3.0 (3.1-3.0)* |
| No. of reflections (unique) | 57,154                  | 32,680          |
| $R_{	ext{work}}$/R$^\text{free}$ (%) | 18.0 (23.2)/22.0 (30.0)* | 24.0 (39.3)/26.8 (44.1)* |
| No. of atoms      | 7,027                   | 10,062          |
| Wilson B-factor   | 36.3                    | 70.3            |
| Average B-factor  | 52.0                    | 91.3            |
| R.m.s deviations  |                         |                 |
| Bond lengths (Å)  | 0.002                   | 0.002           |
| Bond angles (°)   | 0.66                    | 0.80            |
| Ramachandran favoured/outliers (%) | 96.0/0.8 | 96.0/0.2 |
| PDB code         | 5IVX                    | 5IW1            |

* Asterisked numbers correspond to the last resolution shell.
† A pseudo-merohedral twin fraction was estimated by Xtriage in PHENIX.
‡ Refinement $\beta$-interface in solution.
§ A pseudo-merohedral twin fraction was estimated by Xtriage in PHENIX.
NMR reveals pMHC-binding effects on the TCR β-chain domain. The completeness of the backbone assignments of unliganded TCR β-chain (Fig. 3a) allowed us to probe local conformational changes upon binding to its p/MHC ligand. The complex between the TCR ectodomains and P18-I10/H2-Dd is 94.7 kDa and is therefore difficult to characterize by standard NMR methods. Here the use of extensive deuteration of side-chain protons to improve 13C relaxation and the application of TROSY methods at high magnetic fields to improve 15N relaxation allowed us to obtain high-quality NMR spectra of the bound state at room temperature (Fig. 3b). In agreement with the previous SPR and AUC measurements (Fig. 1b,c), B4.2.3 TCR formed a tight complex with P18-I10/H-2Dd under the NMR sample conditions. The exchange between free and bound states of the TCR was slow on the chemical shift timescale, as indicated by a single set of peaks for the complex, with large chemical shift changes relative to the free state (up to 0.5 p.p.m. when scaled relative to the 1H field, as shown along the β-chain sequence in Fig. 5c).

Analysis of the changes in peak positions and intensities revealed two types of effects on the TCR β-chain amide resonances: (1) chemical shift perturbations (Fig. 5c, black bars), indicating a change in the local magnetic environment and (2) conformational exchange-induced line-broadening in the bound state (Fig. 5c, red bars), suggesting a perturbation in μs–ms timescale dynamics or increased solvent exchange rates. Several of the observed chemical shift changes correlate with the displacement of residues in Vβ domain loops seen in the X-ray structures, such as Ser27 in CDR1β, Asp52 in CDR2β and several residues in CDR3β (Fig. 5a, right panel). In addition, the peak intensities of residues 49–53 located in the CDR2β loop were significantly attenuated in the bound form (Fig. 5c). Notably, residues 100–105 located at

Figure 2 | X-ray structure of the complex between TCR and pMHC. (a) Ribbon diagram shows the B4.2.3 αβ TCR (above) focusing its CDR loops on the P18-I10/H2-Dd/β2m complex (below). TCR α-chain is gold, β-chain is green, peptide (shown in stick representation) is cyan, MHC heavy chain is red, and MHC light chain is yellow. (b) enlargement of view of MHC-binding groove and bound peptide. MHC and peptide coloured as in a. CDRs of unliganded TCR α-chain are shown in gold, β-chain in green; of liganded TCR α-chains are magenta and of β-chains are purple. The right hand panel (an ~45° counterclockwise rotation of the left) highlights the large movement of CDR3α residue Phe97. The crossing angle of the TCR on the pMHC, calculated according to Rudolph et al.15, is 30°. (c) Contact map illustrates interactions between TCR and peptide residues (in gold), and between TCR and MHC helices (in red and blue). Data collection and refinement statistics are provided in Table 1. Structural changes between the free and bound forms of the TCR are outlined in Supplementary Fig. 1.
the Vα/Vβ domain interface also showed above average chemical shift perturbations (Fig. 5c), indicating that p/MHC-binding-induced conformational changes in the V domains are not restricted to the CDR loops.

Strikingly, the NMR data revealed long-range effects on the Cβ of the TCR, at the membrane proximal face of the molecule. These changes are highly localized, and cluster near the H3 helix of Cβ (Glu130, Thr138) at the interface with the Cα domain (Fig. 5c). In addition to the shifted peaks, the resonances of several amides in the region were significantly attenuated in the bound form, suggesting further changes in dynamics at or near the H3 and H4 regions. These include Ser127, Lys134, Ser183, Arg187 and Val188, all located at the interface with Cα (highlighted with red asterisks in Fig. 5c and shown as red bars in Fig. 5a, left panel). Since amide chemical shifts can be influenced by the local backbone conformation and hydrogen-bonding geometry, these results point to discrete structural changes in the H3 and H4 regions of the β-chain of the B4.2.3 TCR upon p/MHC binding. The structural changes observed in solution in the region of the H3 helix prompted us to compare available liganded and unliganded X-ray structures of MHC-I-restricted TCR19. Although there are a limited number of X-ray structures of pMHC-I/TCR complexes for which comparison with the unliganded TCR may be made, careful...
Figure 4 | Cross-saturation transfer NMR elucidates intermolecular contacts of the αβ-TCR in solution. (a) Cross-saturation transfer experiment performed on free U-[15N,H]-β-chain-labelled and unlabelled (protonated) α-chain B4.2.3 TCR acquired at 800 MHz, 25 °C. Experimental details are outlined in Methods. The plot shows the normalized peak intensity ratio (I_{saturated}/I_{non-saturated}) as a function of TCRβ residue. The dashed line signifies 1 s.d. of chemical shift change from the average. (b) Mapping of TCRβ residues affected upon cross-saturation transfer (shown in red) on the X-ray structure of the B4.2.3 TCR with β-chain shown as a surface display (light blue) and α-chain shown as cartoon (wheat) with side chains of α-chain residues near the α/β interface shown as sticks.

inspection of 10 pairs of superposed structures in the H3 helix revealed no differences in backbone configuration and no consistent changes in side-chain orientations. Notably, the H3 helix does not participate in any crystallographic contacts in our study.

We additionally carried out NMR titrations of B4.2.3 TCR selectively methyl-labelled in its β-chain with p/MHC to complement our amide-mapping results. Methyl groups, such as Ala Cβ, Ile Cβ1, Leu Cβ1/Cβ2 and Val Cγ1/Cγ2, are highly sensitive probes of side-chain packing within hydrophobic cores of proteins and are less influenced by the molecular size of the system under investigation because of their favourable relaxation properties. The quality of the 2D [1H,13C] HMQC spectrum of consistently folded methyl labelled α-chain, refolded with unlabelled α-chain (Fig. 6a, red), allowed us to probe dynamic changes that occur in the P18-I10/H2-Dd bound state (Fig. 6b, blue). To transfer the methyl assignments to the bound state, we recorded a 3D HMQC-COSY NOESY data set on the P18-I10/H2-Dd/B4.2.3 complex and compared it to a similar experiment recorded for the free state (Supplementary Fig. 2e). Similar to the 15N-TROSY results obtained for β-chain backbone amides (Fig. 5c), we measured highly reproducible slow-timescale changes in peak positions (Fig. 6a, arrows) and intensities (Fig. 6a, asterisks). In particular, we observed significant effects for the methyls of Leu42, Ile45 and Ile47, located on the β-strand of the Vβ domain leading to CDR2β, as well as Val51 located on CDR2β (Fig. 6b, top panel). This corroborates the changes observed in the X-ray structure of the p/MHC-bound TCR relative to the apo structure (Supplementary Fig. 1f). Smaller but statistically significant changes were also observed for the resonances of Leu75, Leu77 and Val87 located near the core of the Vβ domain (Fig. 6b, top panel). Likewise, the change in peak intensity between the free and bound states revealed effects: (1) near and on the CDRs including Val3, Ile47, Val51, Leu94, Val99; (2) near the interface between the Vβ and Cβ domains including Ala80, Val116; and (3) in the H3 and H4 helix regions including Ala132 and Ala190 (Fig. 6b, bottom panel, Fig. 6c).

Mutagenesis suggests a role for the TCR Cβ H3 helix. Our observation that the resonances of residues in and near the Cβ H3 helix of the B4.2.3 TCR undergo significant changes in the bound state led us to examine the functional role of this putative allosteric site in cell-surface expression and signalling. We targeted Cβ residues that demonstrate significant NMR effects, that is, Ser127, Glu130, Asn133, Lys134 and Thr138 (Fig. 5a,c). We examined single Ala substitution mutants of each of these residues for their effects on cell-surface expression when paired with the parental α-chain. As shown in Fig. 7a, Ala mutation of Glu130 or Thr138 abolishes cell-surface expression as shown by anti-Vα2 antibody staining that was indistinguishable from untransfected controls. Notably, Ala mutations at the same residues in soluble β-chain constructs result in inability to refold into functional TCR heterodimers in vitro, consistent with their placement in a critical region at the interface with the α-subunit of the TCR. The remaining three mutants show levels of surface expression identical to the parental receptor and were further analysed for p/MHC binding and TCR activation in stimulation assays. All three mutant transfecants show decreased interleukin (IL)-2 production when compared to the wild-type transfected cells with the Asn133 Ala mutant showing the greatest reduction (Fig. 7b). Comparison of the amount of IL-2 elicited by 1 μM peptide reveals a reduction from 587 ± 45 pg in the parental transfecant to only 8 ± 4 pg in the Asn133A mutant, corresponding to a 98% decrease in IL-2 levels. Similarly, at a 1 μM peptide dose, the Lys134A mutant shows a decrease of 84% from the wild-type IL-2 levels, while the Ser127A mutation exerts a less severe effect on IL-2 levels, revealing a reduction of only 34% compared to the wild type. The severely attenuated signalling by the Asn133A and Lys134A mutants is not caused by defects in antigen recognition as all three mutants bind P18-I10/H2-Dd tetramers with equal avidity and show the same rate of dissociation as the parental transfecant (Fig. 7c). These results emphasize the functional importance of TCR Cβ residues Asn133 and Lys134 in p/MHC-dependent signalling and highlight the role of Glu130 and Thr138 for correct assembly, association with the CD3 co-receptor and subsequent surface expression.

To examine further whether the Asn133A substitution affected the affinity of the mutant TCR for P18-I10/H2-Dd, or the stability of the TCR heterodimer itself, we prepared recombinant Asn133A TCR and compared it with the parental B4.2.3 TCR for binding to immobilized p/MHC in an SPR assay (Supplementary Fig. 7 and Supplementary Table 1). The thermal
stability of the mutated TCR was assessed using differential scanning fluorimetry, and was found to be identical to the parental protein (Supplementary Fig. 8). The SPR-binding curves, analysed both kinetically and at steady state, revealed little or no difference in the kinetic association or dissociation rate constants (k\(_{a}\) and k\(_{d}\) values) as well as the calculated or steady-state determined equilibrium constants (K\(_{D}\) values), indicating that the functional effect of the mutation is not the result of a p/MHC-binding defect, but rather reflects the putative allosteric site.

**Discussion**

A fundamental question in T-cell immunity is the mechanism by which p/MHC engagement by the TCR is relayed to the associated CD3 subunits to initiate intracellular signalling. Signal transduction likely occurs through ligand-induced conformational changes in the TCR constant domains, which are then transmitted to the CD3 subunits\(^{15,36–38}\). Such structural changes have been difficult to visualize crystallographically, because of the relatively low resolution typically seen for these regions in crystal structures. NMR offers an alternative approach to identify subtle changes in the local magnetic environment of proteins and structures. NMR studies have revealed lipid-sensitive conformational changes along the \(_{\alpha}\) and \(_{\beta}\) domains of the TCR structure. Two types of observed changes are highlighted with different colours: residues with significantly attenuated resonances (>1 s.d. from the average) in the bound form are shown in red, while residues with significant chemical shift changes are in blue. In the middle panel, the tertiary structure of the \(\alpha\)/\(\beta\) complex is highlighted with different colours: residues with significantly attenuated resonances (chemical shift changes upon MHC-I binding are shown as sticks on the C\(_{\beta}\) and 1:1 MHC-bound (blue) state of the TCR, using two samples that were labelled at the average. Residues with significantly attenuated resonances in the bound form are shown as red bars, while unassigned and Pro residues are in grey. Red stars highlight C\(_{\alpha}\) domain resonances that disappear upon p/MHC binding, and that are also illustrated in the structure diagram above (a). The large chemical shift change observed for Glu130 upon p/MHC binding is highlighted in the inset.

**Figure 5 | pMHC-induced conformational changes on the TCR \(_{\beta}\)-chain domains.** (a) TCR \(_{\beta}\)-chain residues with significant amide \(^{15}\)N-\(^1\)H TROSY-HSQC chemical shift changes upon MHC-I binding are shown as sticks on the \(\beta\)- and \(\beta\)-domains of the \(\alpha\)-\(\beta\)-TCR structure. Two types of observed changes are highlighted with different colours: residues with significantly attenuated resonances (>1 s.d. from the average) in the bound form are shown in red, while residues with significant chemical shift changes are in blue. In the middle panel, the tertiary structure of the \(8\)- (beige/green)/\(H2\)- (grey) complex is shown with \(\beta\)m (yellow) and \(\beta\)I10-bound peptide (cyan sticks). (b) Overlays of representative regions from TROSY-HSQC spectra recorded in the free (red) and 1:1 MHC-bound (blue) state of the TCR, using two samples that were \(^{15}\)N, \(^{2}\)H, \(^{13}\)C-labelled at the \(\beta\)-chain and unlabelled \(\alpha\)-chain (as shown in Fig. 3a,b). Pairs of peaks that correspond to the same residues in the free and bound forms are connected by dotted arrows. (c) Summary of combined \(^{15}\)N/\(^{1}\)H chemical shift changes along the \(\beta\)-chain sequence, scaled relative to \(\alpha\). The dashed line signifies 1 s.d. of combined chemical shift change from the average. Residues with significantly attenuated resonances in the bound form are shown as red bars, while unassigned and Pro residues are in grey. Red stars highlight \(\beta\)-domain resonances that disappear upon p/MHC binding, and that are also illustrated in the structure diagram above (a). The large chemical shift change observed for Glu130 upon p/MHC binding is highlighted in the inset.
conformational changes in the signalling domains of the CD3εζ homodimer and the CD3ζ subunit.

Here we use NMR to elucidate changes in TCR dynamics upon binding to the p/MHC ligand. Using a complementary combination of backbone amide and side-chain methyl probes, we extensively map ligand-induced chemical shift perturbations along the TCR β-chain. Consistent with our X-ray structures of the free and p/MHC-bound forms of the receptor, the Vβ CDR loops that directly engage the p/MHC ligand show large changes in our NMR spectra. In particular, we report significant chemical shift perturbations for the amide resonances of Ser27 on CDR1β, Asp52 on CDR2β and several CDR3β residues, as well as the methyl resonances of Val51 on CDR2β and Leu94, Val99 on the hypervariable loop region. Notably, we also observe significant NMR effects on sites located near the H3 and H4 helices of the hypervariable loop region. Notably, we also observe significant NMR effects on sites located near the H3 and H4 helices of the hypervariable loop region.

Figure 6 | Methyl probes of TCR and pMHC complex formation. (a) 2D 1H-13C HMQC spectra of AILV 13C-methyl labelled U-[15N, 2H] β-chain B4.2.3 TCR in the free (red) and 1:1 P18-I10/H2-D6 bound (blue) states acquired at 800 MHz, 25 °C. Changes in chemical shift position are indicated with arrows, while changes in chemical shift intensity due to line broadening are indicated by asterisks. Stereo-specific chemical shift assignments are indicated.

Assignment of AILV-methyl chemical shifts is outlined in Supplementary Figs 2–5. (b) Plot of chemical shift deviation (CSD in p.p.m.; top) and normalized peak intensity ratio (Ibound/Ifree; bottom) as a function of TCRβ methyl residue number. The dashed line signifies ± 1 s.d. of combined chemical shift change from the average. Affected residues are indicated. (c) Mapping of Ala, Ile, Leu and Val methyl probes on the X-ray structure of B4.2.3 TCR with α-chain coloured wheat and β-chain coloured grey. Residues that are affected in either CSD or intensity ratio between the free and bound states are indicated.
the amides of Glu130 and Thr138 and the methyls of Ala132 and Ala190. The importance of the H3 helix for signalling is further corroborated by functional data obtained for selected mutants that inhibit signalling without affecting the expression levels of the TCR, its stability or its ability to recognize the p/MHC.

The potential of TCR self-association having an impact on the observed chemical shift and intensity changes is ruled out by several lines of evidence. First, our AUC data are consistent with a fully monomeric TCR sample. Second, the $^{15}$N and $^{13}$C linewidths are consistent with a predominantly monomeric TCR form of the heterodimer in solution, and remain very similar over a range of concentrations from 70 to 250 $\mu$M. Finally, the NMR spectra show the same slow-exchange process and changes over a range of TCR concentrations from 70 to 250 $\mu$M. These results conclusively support the view that the significant distal changes observed by NMR arise from an allosteric communication mechanism, as opposed to a secondary binding site or transient dimerization.

Close inspection of interactions near the H3 region in the crystal structures of the free and p/MHC-bound forms of the TCR suggests a possible explanation for the observed NMR chemical shift perturbations at this site. The interface between the C$\alpha$ and C$\beta$ domains of the TCR is composed primarily of polar and charged residues that form a network of electrostatic interactions$^{22}$. In particular, Tyr125$\alpha$ in the unliganded TCR interacts with Asn133$\beta$ and Lys134$\beta$ in one of the three molecules in the asymmetric unit (Fig. 8a) and has long-range contacts with these residues in the other two molecules. However, a displacement of the C$\alpha$ domain upon p/MHC-binding promotes the formation of a Glu121$\alpha$-Lys134$\beta$ salt-bridge in the bound state (Fig. 8b). Notably, the side chains of Arg187$\beta$ and Asp142$\alpha$ interact in both the free and the bound structures (Fig. 8a,b). These structural displacements are consistent with the measured chemical shift perturbations for the Glu130$\beta$, Thr138$\beta$ and the broadening of the Lys134$\beta$, Arg187$\beta$ backbone amide resonances (Fig. 5c), as well as the broadening of the Ala132$\beta$ (on H3), Ala190$\beta$ (on H4) methyl resonances (Fig. 6b). Thus, solution NMR mapping and X-ray structural data are consistent with a systematic reorganization of the C$\alpha$/C$\beta$ interface involving a remodelling of electrostatic interactions near the H3 and H4 regions of C$\beta$. Taken together, our results provide a link between p/MHC binding at the CDR loops and dynamic changes in the TCR C$\beta$ domain that are critical for signalling$^{33}$. The interface between the C$\alpha$ and the C$\beta$ domains plays an essential role for the stability and assembly of the TCR heterodimer, as shown both in vitro and in vivo in a recent study$^{44}$. In accordance, residues at the C$\alpha$/C$\beta$ domain interface near the H3 helix are highly conserved across $\alpha$- and $\beta$-chain sequences from different species, which could result from their role in stabilizing the TCR itself as well as communicating an activation signal to CD3 (Fig. 8c).

Asn133$\beta$ and Lys134$\beta$ are not 100% conserved, residues with potential for hydrogen bond formation are retained at these positions, suggesting that the interface interactions with Tyr125$\alpha$ and Glu121$\alpha$ are crucial for TCR stability and CD3 signalling. A plausible structural mechanism for the transmission of conformational changes from the CDRs to the C$\beta$ distal sites is suggested by the observation of affected sites in the V$\beta$/C$\beta$ linker region, in particular Val116$\beta$, which shows significant line broadening in our NMR spectra. It is therefore conceivable that dynamically driven p/MHC-induced allosteric changes in the constant regions of the TCR, supported both by NMR data presented here and previous hydrogen/deuterium exchange experiments$^{46}$, could potentiate interactions with CD3$\gamma$ and $\delta$, which, according to recent NMR studies, interact only weakly with the free TCR$^{25,26}$.

The role of the $\alpha$-chain in mediating these structural changes cannot be directly addressed with the $\beta$-chain labelling scheme used here. However, similar effects on the $\alpha$-chain structure are implied by the fact that most sites that undergo conformational

---

**Figure 7 | Expression and function of parental and C$\beta$-mutant TCRs in transfected of $\alpha$$\beta$ cells.** (a) Staining of nontransfected (NTF), wild type (WT) and the indicated B4.2.3 TCR C$\beta$ mutants with PE-conjugated anti-V$\alpha$2 antibody as analysed by flow cytometry. (b) IL-2 amounts in culture supernatants of nontransfected (NTF), wild type (WT) and the indicated B4.2.3 TCR C$\beta$ mutants stimulated for 16 h with graded concentrations of P18-I10 peptide in the presence of A20 cells. IL-2 levels were quantified by ELISA. (c) Dissociation of P18-I10/H2-D$\beta$ tetramers from WT and mutant TCR expressing transfectants detected by flow cytometry at 5-min intervals ranging from 0 to 30 min. Error bars represent mean ± s.d.

**Figure 8 | Sequence conservation at the C$\alpha$- and C$\beta$-domain interface near the H3 helix of the TCR.** (a) Free and (b) bound X-ray structures of the B4.2.3 $\alpha$$\beta$ TCR dimer showing a network of electrostatic interactions (dashed lines) at the interface between the $\alpha$- and $\beta$-subunit constant domains. The $\alpha$ and C$\beta$ domains are shown with yellow/beige and cyan/green in the free/bound structures, respectively. Functionally important residues identified by NMR to show significant changes upon MHC binding are highlighted on the structure. (c) Sequence conservation patterns within the same regions of the C$\alpha$ and C$\beta$ domains as in a.b.
transitions are localized near the α/β-interface. This is consistent with an earlier crystallographic study of a human TCR that revealed extensive conformational rearrangement of the BC and DE turns on C2 (ref. 46) as well as recent fluorescence47 and hydrogen/deuterium exchange studies48, which showed that binding of the cognate p/MHC ligand induces long-range effects on the Cx A-B loop region. The structural basis of such changes at the TCR α/β-interface, and their impact on interactions with the CD3 co-receptor should be investigated in future studies.

Methods

Protein expression and purification. The expression and purification of P18-I10/H2-D₃ was performed using standardized protocols48,49. Briefly, cDNAs encoding the entire coding sequence of the B4.2.3 TCR α- and β-chains were amplified by RT-PCR from RNA isolated from the B4.2.3 hybridoma16. DNAs encoding the extracellular portions of the TCR chains up to, but not including, the membrane-proximal cysteine, were cloned into pET21b (Novagen) and then expressed in LB-broth at 37 °C after transformation of Escherichia coli BL21(DE3) (Novagen). (All reference to TCR V chain numbering is sequential beginning with the mature TCR chains). Following the strategy described by Boulter et al.50 for human TCRs, an interchain disulfide was engineered between the constant domains of the TCR α- and β-chains by replacing Thr163 of Cx and Ser167 of Cβ with Cys, and the unpaired Cys181 in the Cβ domain was mutated to Ala. TCR α⁻β⁻ was assembled separately as inclusion bodies, solubilized in 6 M guanidine-HCl/0.1 mM dithiothreitol (DTT), mixed together and reeled for purification as described for P18-I10/H2-D₃.

Crystallization and structure determination. Equal volumes of purified B4.2.3 TCR and P18-I10/H2-D₃, each at 7 mg ml⁻¹, were mixed and allowed to incubate for 30 min at room temperature before crystallization trials. Diffraction quality crystals of the complex were grown in hanging drops at 18 °C in 15% PEG 3350, 0.15 M MgCl₂, cryoprotected in 15% ethylene glycol in 20% PEG 3350, 0.2 M MgCl₂, and frozen in liquid nitrogen. Crystals of free B4.2.3 were grown in hanging drops at 18 °C in 16% PEG 4000, 0.1 M TRIS pH 8.8, 0.2 M MgCl₂, cryoprotected in 15% ethylene glycol in the crystallization solution and frozen in liquid nitrogen. Diffraction data were collected at the National Synchrotron Light Source, Brookhaven and, on Soleil X29 equipped with an ADSC Q315 detector. Data were indexed and scaled with HKL2000 (ref. 51). Data collection and refinement statistics are reported in Table 1. Molecular replacement solutions were readily found for the TCR and H2-D₃ with Phaser52 using the mumin AH12.2 TCR (PDB 1LP9) and the previously determined structure of H2-D₃ (PDB 1DHH) as search models. For the unliganded B4.2.3 TCR, the best solution was in the P31 space group, but analysis of the data by Xtriage indicated pseudo-merohedral Cc domains of the TCR for human TCRs, an interchain disulfide was engineered between the constant domains of the TCR α- and β-chains by replacing Thr163 of Cx and Ser167 of Cβ with Cys, and the unpaired Cys181 in the Cβ domain was mutated to Ala. TCR α⁻β⁻ was assembled separately as inclusion bodies, solubilized in 6 M guanidine-HCl/0.1 mM dithiothreitol (DTT), mixed together and reeled for purification as described for P18-I10/H2-D₃.

Surface plasmon resonance. BirA-tagged H2-D₃ reeled with either the P18-I10 peptide or with a motif (MTF) peptide (AGPARAAAL) was biotinylated using BirA ligase and biotin (Avidity, LLC) according to the manufacturer’s instructions. Peptide or with a motif (MTF) peptide (AGPARAAAL) was biotinylated using BirA ligase and biotin (Avidity, LLC) according to the manufacturer’s instructions. The expression and purification of Protein expression and purification were characterized in the primary AUC experiments with a concentration range of 0.1–10 µM. For the binary interactions, equimolar mixtures of B4.2.3 or with mutated CDR3 residues, at various concentrations, was injected over TCR and P18-I10/H2-D₃, each at 7 mg ml⁻¹, were mixed and allowed to incubate for 30 min at room temperature before crystallization trials. Diffraction quality crystals of the complex were grown in hanging drops at 18 °C in 16% PEG 4000, 0.1 M TRIS pH 8.8, 0.2 M MgCl₂, cryoprotected in 15% ethylene glycol in the crystallization solution and frozen in liquid nitrogen. Diffraction data were collected at the National Synchrotron Light Source, Brookhaven and, on Soleil X29 equipped with an ADSC Q315 detector. Data were indexed and scaled with HKL2000 (ref. 51). Data collection and refinement statistics are reported in Table 1. Molecular replacement solutions were readily found for the TCR and H2-D₃ with Phaser52 using the mumin AH12.2 TCR (PDB 1LP9) and the previously determined structure of H2-D₃ (PDB 1DHH) as search models. For the unliganded B4.2.3 TCR, the best solution was in the P31 space group, but analysis of the data by Xtriage indicated pseudo-merohedral Cc domains of the TCR for human TCRs, an interchain disulfide was engineered between the constant domains of the TCR α- and β-chains by replacing Thr163 of Cx and Ser167 of Cβ with Cys, and the unpaired Cys181 in the Cβ domain was mutated to Ala. TCR α⁻β⁻ was assembled separately as inclusion bodies, solubilized in 6 M guanidine-HCl/0.1 mM dithiothreitol (DTT), mixed together and reeled for purification as described for P18-I10/H2-D₃.

Analytical ultracentrifugation. Analytical ultracentrifugation experiments were conducted in an XL-1 analytical ultracentrifuge (Beckman Coulter, Indianapolis, IN) with an An50Ti rotor, following standardized protocols53. Briefly, protein samples were prepared by dilution of concentrated stocks with the working buffer (25 mM of HEPES, pH 7.2, 150 mM NaCl). Individual protein molecules were characterized in the primary AUC experiments with a concentration range of 0.1–10 µM. For the binary interactions, equimolar mixtures of B4.2.3 TCR + P18-I10/H2-D₃ or B4.2.3 TCR + MTF/H2-D₃ were prepared in a concentration series of 0.1–20 µM. The samples were loaded into standard double-sector coal-forest filled epon centriplates with 12- or 3-mm path length and sapphire windows. The sedimentation process of the protein molecules was monitored using both Rayleigh interference and ultraviolet absorbance at 280 nm detection at 20 °C and 50,000 r.p.m. The acquired sedimentation velocity data were analysed with SEDFIT using the c(s) sedimentation coefficient distribution approach54, from which the signal-weighted-average sedimentation coefficient (cₙ) was obtained by integration. To determine the binding affinity, the isotherm of a series of macromolecular concentrations was fitted with the 1:1 hetero-dimerization model: where cₐ and cₜₐ denote the total molar concentration for A and B, cₐ indicates the molar concentration of the free component, s denotes the sedimentation coefficient, τ denotes the extinction coefficient and KₐA (Kₐ = 1/KₐA) is the equilibrium association-binding constant. In the analysis, λₐ and λₜₐ were fixed at the experimentally determined values, while KₐB and sₐB were subject to optimization, through nonlinear regression. The error surface projection analysis was exploited to determine the error intervals of the best-fit KₐB values at a 95% confidence level.

NMR sample preparation and backbone assignments. U-[15N,13C]-labelled B4.2.3 TCR samples for NMR were prepared by substituting the TCR β-chain growth medium with M9 minimal media in 3H₂O containing 2 g l⁻¹ 13C₂, 11C₂ H₂O (Sigma #552215) and 1 g l⁻¹ 15N HCl. To promote overexpression, we monitored using both Rayleigh interference and ultraviolet absorbance at 280 nm detection at 20 °C and 50,000 r.p.m. The acquired sedimentation velocity data were analysed with SEDFIT using the c(s) sedimentation coefficient distribution approach54, from which the signal-weighted-average sedimentation coefficient (cₙ) was obtained by integration. To determine the binding affinity, the isotherm of a series of macromolecular concentrations was fitted with the 1:1 hetero-dimerization model: where cₐ and cₜₐ denote the total molar concentration for A and B, cₐ indicates the molar concentration of the free component, s denotes the sedimentation coefficient, τ denotes the extinction coefficient and KₐA (Kₐ = 1/KₐA) is the equilibrium association-binding constant. In the analysis, λₐ and λₜₐ were fixed at the experimentally determined values, while KₐB and sₐB were subject to optimization, through nonlinear regression. The error surface projection analysis was exploited to determine the error intervals of the best-fit KₐB values at a 95% confidence level.

Analytical ultracentrifugation. Analytical ultracentrifugation experiments were conducted in an XL-1 analytical ultracentrifuge (Beckman Coulter, Indianapolis, IN) with an An50Ti rotor, following standardized protocols53. Briefly, protein samples were prepared by dilution of concentrated stocks with the working buffer (25 mM of HEPES, pH 7.2, 150 mM NaCl). Individual protein molecules were characterized in the primary AUC experiments with a concentration range of 0.1–10 µM. For the binary interactions, equimolar mixtures of B4.2.3 TCR + P18-I10/H2-D₃ or B4.2.3 TCR + MTF/H2-D₃ were prepared in a concentration series of 0.1–20 µM. The samples were loaded into standard double-sector coal-forest filled epon centriplates with 12- or 3-mm path length and sapphire windows. The sedimentation process of the protein molecules was monitored using both Rayleigh interference and ultraviolet absorbance at 280 nm detection at 20 °C and 50,000 r.p.m. The acquired sedimentation velocity data were analysed with SEDFIT using the c(s) sedimentation coefficient distribution approach54, from which the signal-weighted-average sedimentation coefficient (cₙ) was obtained by integration. To determine the binding affinity, the isotherm of a series of macromolecular concentrations was fitted with the 1:1 hetero-dimerization model: where cₐ and cₜₐ denote the total molar concentration for A and B, cₐ indicates the molar concentration of the free component, s denotes the sedimentation coefficient, τ denotes the extinction coefficient and KₐA (Kₐ = 1/KₐA) is the equilibrium association-binding constant. In the analysis, λₐ and λₜₐ were fixed at the experimentally determined values, while KₐB and sₐB were subject to optimization, through nonlinear regression. The error surface projection analysis was exploited to determine the error intervals of the best-fit KₐB values at a 95% confidence level.
ILV* and AILV-methyl sample preparation and methyl assignments.

Methyl-labelled samples of the TCR β-chain were prepared according to standard protocols and selectively labelled with 13C- and 2H-labeling patterns, referred to as ILV* and AILV herein. All isotopes were obtained from ISOTEC Stable Isotopes (Sigma-Aldrich), and the catalogue numbers are indicated below. ILV*-methyl (13C CH3 for Ile, 15N CH3 for Leu and Val) was bound to β-chain B4.2.3 TCR was prepared in M9 minimal media culture in 15N, D2O supplemented with 313C, 2H glucose (Sigma #552151) and 13C methyl out-and-back experiment27 was recorded on 225M 1H-13C SOFAST HMQC spectra were recorded at 800 MHz, 25°C for unambiguous assignment of side-chain methyl resonances in the AILV side-chain methyl assignments were validated and stereospecifically confirmed that the TCR structure and monomeric state were identical in the B4.2.3 TCR or its mutants were stained with phycoerythrin (PE)-conjugated anti-Vβ2 (BD Pharmingen cat. no. 553289 used at 1/100 dilution) and PE-conjugated anti-PE Microbeads (Miltenyi Biotec). For stimulation assays, 5 × 104 parental 5×104 β-chain expressing parental or mutant B4.2.3 TCR were stimulated for 16 h with graded concentrations of P18-110 peptide in the presence of an equal number of the BALB/c-derived B lymphoma line A20 as presenting cells in 96-well flat-bottom plates (Costar). Supernatants were diluted 1:20 for measurements of secreted IL-2 levels by ELISA (BD-Pharmingen) following the manufacturer’s instructions. The results of three independent experiments were combined to obtain the means and their s.d.s. For tetramer binding and dissociation assays, 105 18S β-chain cells expressing parental or mutant B4.2.3 TCR were incubated with 200 ng of PE-labeled P18-110/H2-Dd tetramer. At various time points during incubation at room temperature, cells were analysed by flow cytometry for residual bound tetramer.

Data availability. The refined coordinates and structure factors for the X-ray structures of free B4.2.3 TCR and P18-110/H2-D2-bound B4.2.3 TCR have been deposited in the Protein Data Bank (www.rcsb.org) with PDB IDs 5W1D and 5IVX, respectively. NMR assignments for the backbone and side-chain methyl chemical shifts of the β-chain of the B4.2.3 TCR have been deposited into the Biological Magnetic Resonance Data Bank (http://www.bmrbr.wisc.edu) under accession number 26977. All other data are available from the corresponding authors upon reasonable request.

References

1. Germain, R. N. & Margulies, D. H. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11, 403–450 (1993).
2. Blum, J. S., Wearsch, P. A. & Cresswell, P. Pathways of antigen processing. Annu. Rev. Immunol. 31, 443–473 (2013).
3. Davis, M. M. & Chien, Y.-H. in Fundamental Immunology, Seventh Edition (ed. W. E. Paul) 279–305 (Walters Kluwer Lippincott Williams & Wilkins, 2013).
4. Samelson, L. E., Harford, J. B. & Klausner, R. D. Identification of the T3 glycoprotein heavy subunit. Cell 43, 223–231 (1985).
5. Brenner, M. B., Trowbridge, I. S. & Strominger, J. L. Cross-linking of human T cell receptor proteins: association between the T cell idiotype beta subunit and the T3 glycoprotein heavy subunit. Cell 40, 183–190 (1985).
6. Guy, C. S. & Vignali, D. A. Organization of proximal signal initiation at the TCR/CD3 complex. Immunol. Rev. 232, 7–21 (2009).
7. Hall, C. et al. Requirements for cell surface expression of the human TCR/CD3 complex in non-T cells. Int. Immunol. 3, 359–368 (1991).
8. Manolios, N., Letoumeur, F., Bonifacino, J. S. & Klausner, R. D. Pairwise, competitive and inhibitory interactions describe the assembly and probable structure of the T-cell antigen receptor. EMBO J. 10, 1643–1651 (1991).
9. Notarangelo, L. D. Immunodeficiency and immune dysregulation associated with proximal defects of T cell receptor signaling. Curr. Opin. Immunol. 31, 97–104 (2014).
10. Chetnou, L. & Bluestone, J. A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol. 7, 622–632 (2007).
11. Phan, G. Q. & Rosenberg, S. A. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 20, 289–297 (2013).
12. Ozten, J., Hasson, N. J. & Jakobsen, B. K. ImmTACs for targeted cancer therapy: Why, what, how, and which. Mol. Immunol. 67, 67–74 (2015).
13. Kuhns, M. S. & Davis, M. M. TCR signaling emerges from the sum of many parts. Front Immunol. 3, 159 (2012).
14. Gil, D., Schrum, A. G., Alarcon, B. & Palmer, E. T cell receptor engagement by peptide-MHC ligands induces a conformational change in the CD3 complex of thymocytes. J. Exp. Med. 201, 517–522 (2005).
15. Aivazian, D. & Stern, L. J. Phosphorylation of T cell receptor zeta is regulated by a lipid dependent folding transition. Nat. Struct. Biol. 7, 1023–1026 (2000).
16. Kozloski, S. et al. Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature 349, 74–77 (1991).

17. Plaksin, D., Polakova, K., McPhie, P. & Margulies, D. H. A three-domain T cell receptor is biologically active and specifically stains cell surface MHC/peptide complexes. J. Immunol. 158, 2218–2227 (1997).

18. Stone, J. D., Chervin, A. S. & Kranz, D. M. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunity 126, 165–176 (2005).

19. Rossjohn, J. et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33, 169–200 (2015).

20. Garcia, K. C. & Adams, E. J. How the T cell receptor sees antigen—a structural view. Cell 122, 333–336 (2005).

21. Marrack, P., Scott-Browne, J. P., Dai, S., Gapin, L. & Kappler, J. W. Evolutionarily conserved amino acids that control TCR-MHC interaction. Annu. Rev. Immunol. 26, 171–203 (2008).

22. Rudolph, M. G., Stanfield, R. L. & Wilson, I. A. How TCRR bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24, 419–466 (2006).

23. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946–950 (1993).

24. Reiser, J. B. et al. A T cell receptor CDRbeta loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity 16, 345–354 (2002).

25. He, Y. et al. Identification of the docking site for CD3 on the T cell receptor beta chain by solution NMR. J. Biol. Chem. 290, 19796–19805 (2015).

26. Natarajan, A. et al. Structural model of the extracellular assembly of the TCR-CD3 complex. Cell Rep. 14, 2833–2845 (2016).

27. Tugarinov, V. & Kay, L. E. Ile, Leu, and Val methyl assignments of the 723-residue malate synthase G using a new labeling strategy and novel NMR methods. J. Am. Chem. Soc. 125, 13868–13878 (2003).

28. Tugarinov, V., Kanelis, V. & Kay, L. E. Isopeptide labeling strategies for the study of high-molecular weight proteins by solution NMR spectroscopy. Nat. Protoc. 1, 749–754 (2006).

29. Rossi, P., Xia, Y., Khanna, N., Veglia, G. & Kalodimos, C. G. 13C and 13C- SOFAST-HMQC editing enhances 3D-NOESY sensitivity in highly deuterated, selectively [1H,13C]-labeled proteins. J. Biomol. NMR 66, 259–271 (2016).

30. Shem, Y. & Bax, A. Protein structural information derived from NMR chemical shifts and the neural network program TALOS-N. Methods Mol. Biol. 1260, 17–32 (2015).

31. Kabcsch, W. & Sander, C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577–2637 (1983).

32. Lipari, G. & Szabo, A. Model-free approach to the interpretation of nuclear magnetic resonance spectroscopy in macromolecules. 2. Analysis of experimental results. J. Am. Chem. Soc. 104, 4559–4570 (1982).

33. Berjanski, M. V. & Wishart, D. S. A simple method to predict protein flexibility using secondary chemical shifts. J. Am. Chem. Soc. 127, 14970–14971 (2005).

34. Takahashi, H., Nakanishi, T., Kami, K., Arata, Y. & Shimada, I. A novel NMR method for determining the interfaces of large protein-protein complexes. Nat. Struct. Biol. 7, 220–223 (2000).

35. Ollerenshaw, J. E., Tugarinov, V. & Kay, L. E. Methyl TROSY: explanation and application. Magn. Reson. Chem. 41, 843–852 (2003).

36. Sun, Z. J., Kim, S. K., Wagner, G. & Reinherz, E. L. Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an extracellular assembly of the clonotypic alphabeta T cell receptor-CD3 complex. J. Mol. Biol. 323, 820–827 (2007).

37. Gil, D., Schamel, W. M., Montoya, M., Sanchez-Madrid, F. & Alcaron, B. Recruitment of Nck by CD3 epsilon reveals a ligand-induced conformational change essential for T cell receptor signaling and synapse formation. Cell 109, 901–912 (2002).

38. Xu, C. et al. Regulation of T cell receptor activation by dynamic membrane binding of the CD3epsilon cytoplasmic tyrosine-based motif. Cell 135, 702–713 (2008).

39. Vanani, L. et al. Solution mapping of T cell receptor docking footprints on peptide-MHC. Proc. Natl Acad. Sci. USA 104, 13080–13085 (2007).

40. Hawse, W. F. et al. TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility. J. Immunol. 192, 2885–2891 (2004).

41. Sun, Z. Y. et al. Solution structure of the CD3epsilon delta delta ectodomain and comparison with CD3epsilonlonga as a basis for modeling T cell receptor topology and signaling. Proc. Natl Acad. Sci. USA 101, 16867–16872 (2004).

42. Duchardt, E., Sigalov, A. B., Aivazian, D., Stern, L. J. & Schwab, H. Structural induction of the T-cell receptor zeta-chain upon lipid binding investigated by CD3epsilon NMR spectroscopy. Chromosome 8, 820–827 (2007).

43. Kuhns, M. S. & Davis, M. M. Disruption of extracellular interactions impairs T cell receptor-CD3 complex stability and signaling. Immunity 26, 357–369 (2007).
Author contributions
K.N., A.C.M., A.B., D.H.M. and N.G.S. designed research, interpreted data and wrote the paper. K.N., J.J., R.W. and L.F.B. prepared samples, performed crystallization and X-ray structure determination, and SPR experiments. H.Z. and P.S. performed AUC experiments and analysed and interpreted AUC data. A.C.M., N.G.S., K.N. and J.Y. prepared isotopically labelled samples and performed NMR experiments. A.C.M., N.G.S. and V.K.K. analysed NMR data. K.N. and M.E.T. performed cell-transfectant experiments.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing interests: The authors declare no competing financial interests.

How to cite this article: Natarajan, K. et al. An allosteric site in the T-cell receptor Cβ domain plays a critical signalling role. Nat. Commun. 8, 15260 doi: 10.1038/ncomms15260 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017